Equities research analysts expect Biopharmx Corp (NASDAQ:BPMX) to announce earnings per share of ($0.06) for the current quarter, according to Zacks. Three analysts have made estimates for Biopharmx Corp’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.07). Biopharmx Corp reported earnings per share of ($0.12) during the same quarter last year, which would suggest a positive year over year growth rate of 50%. The firm is expected to announce its next quarterly earnings report on Tuesday, December 12th.

On average, analysts expect that Biopharmx Corp will report full-year earnings of ($0.24) per share for the current year, with EPS estimates ranging from ($0.28) to ($0.20). For the next year, analysts expect that the firm will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.25) to ($0.15). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Biopharmx Corp.

Biopharmx Corp (NASDAQ:BPMX) last posted its quarterly earnings data on Wednesday, September 13th. The company reported ($0.06) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.06). Biopharmx Corp had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million.

A number of research firms have weighed in on BPMX. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of Biopharmx Corp in a report on Tuesday, September 19th. Maxim Group restated a “buy” rating and set a $1.50 target price (down previously from $3.00) on shares of Biopharmx Corp in a report on Wednesday, September 13th.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/22/zacks-brokerages-expect-biopharmx-corp-bpmx-to-announce-0-06-eps.html.

In other Biopharmx Corp news, major shareholder Franklin Resources Inc purchased 250,000 shares of Biopharmx Corp stock in a transaction dated Tuesday, August 1st. The shares were acquired at an average cost of $0.34 per share, with a total value of $85,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Several hedge funds have recently modified their holdings of BPMX. Virtu KCG Holdings LLC increased its position in shares of Biopharmx Corp by 366.2% during the second quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock worth $241,000 after purchasing an additional 395,424 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Biopharmx Corp by 324.6% during the second quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock worth $927,000 after purchasing an additional 1,478,338 shares in the last quarter. Finally, Vivo Capital LLC increased its position in shares of Biopharmx Corp by 10.0% during the second quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock worth $6,752,000 after purchasing an additional 1,282,052 shares in the last quarter.

Biopharmx Corp (BPMX) traded down 15.5517% on Friday, reaching $0.2449. The company had a trading volume of 3,280,777 shares. The stock’s 50-day moving average is $0.30 and its 200-day moving average is $0.44. The company’s market capitalization is $19.51 million. Biopharmx Corp has a 52 week low of $0.19 and a 52 week high of $0.90.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.